Enhanced Therapeutic Microvesicles from Probiotic Bacteria

This inventive concept enhances the therapeutic efficacy, production, and delivery of microvesicles derived from probiotic bacteria, addressing limitations of existing methods and compositions.

The original patent disclosed therapeutic microvesicles of probiotic bacteria, but had limitations in terms of production efficiency, targeted delivery, and stability. This new inventive concept solves these problems by introducing novel methods for enhancing therapeutic efficacy, large-scale production, and personalized delivery.

The inventive concept comprises five key aspects: (1) encapsulating microvesicles in liposomes or nanoparticles for targeted delivery; (2) a system for large-scale production of microvesicles in a controlled bioreactor environment; (3) a composition of microvesicles derived from multiple probiotic bacterial strains with improved stability and shelf life; (4) a method for personalizing the therapeutic effect of microvesicles based on an individual's microbiome profile; and (5) a microvesicle-based vaccine with enhanced immune response. These aspects work together to provide a more efficient, effective, and personalized approach to therapeutic microvesicle delivery.

The new claims introduce novel and non-obvious solutions to the limitations of the original patent, including targeted delivery, large-scale production, and personalized therapy. The combination of these aspects provides a unique and inventive approach to therapeutic microvesicle technology.

Alternative embodiments may include different types of nanoparticles or liposomes for delivery, varying bioreactor conditions for production, or additional probiotic bacterial strains for composition. Variations may also include different administration routes or dosing regimens for personalized therapy.

This inventive concept has significant commercial potential in the fields of pharmaceuticals, biotechnology, and healthcare. The targeted delivery and personalized therapy aspects may be particularly valuable in treating specific diseases or conditions, such as inflammatory bowel disease or cancer. The large-scale production system may also be attractive to companies seeking to commercialize therapeutic microvesicle products.